Penam Laboratories Limited Balance Sheet(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
EQUITY AND LIABILITIES
|
640.60 |
558.36 |
612.62 |
560.35 |
468.51 |
|
Total equity
|
573.53 |
496.22 |
456.58 |
402.97 |
358.76 |
|
Total liabilities
|
67.06 |
62.14 |
156.04 |
157.38 |
109.75 |
|
Non - Current liabilities
|
3.53 |
3.36 |
3.18 |
2.98 |
3.00 |
|
Current liabilities
|
63.53 |
58.78 |
152.86 |
154.40 |
106.75 |
|
ASSETS
|
640.60 |
558.36 |
612.62 |
560.35 |
468.51 |
|
Non-Current assets
|
142.49 |
104.31 |
35.31 |
90.66 |
92.94 |
|
Current assets
|
498.10 |
454.06 |
577.31 |
469.70 |
375.57 |
Penam Laboratories Limited CashFlow Statement(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
Net cash from/(used in) operating activities
|
54.04 |
-10.53 |
-51.66 |
-23.84 |
34.78 |
|
Net cash from/(used in) investing activities
|
-51.14 |
11.41 |
12.53 |
7.25 |
0.46 |
|
Net increase /(decrease) in cash and cash equivalents
|
2.90 |
0.88 |
-39.13 |
-16.60 |
35.24 |
|
Cash and cash equivalents at the beginning of the year
|
71.38 |
70.50 |
109.64 |
126.23 |
90.99 |
|
Cash and cash equivalents at the end of the year
|
74.29 |
71.38 |
70.50 |
109.64 |
126.23 |
Penam Laboratories Limited Finacial Ratios(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
EBITDA Margin
|
36.23% |
13.44% |
13.63% |
12.03% |
13.20% |
|
EBIT Margin
|
29.13% |
12.97% |
13.27% |
11.66% |
12.67% |
|
Return on Equity (ROE)
|
13.47% |
7.99% |
11.76% |
10.95% |
9.00% |
|
Return on Capital Employed (ROCE)
|
20.15% |
10.58% |
15.96% |
14.91% |
12.32% |
|
Assets Turnover Ratio
|
0.62 |
0.73 |
0.90 |
0.93 |
0.75 |
|
Return on Assets
|
12.06% |
7.10% |
8.77% |
7.87% |
6.89% |
|
Net Profit Margin
|
19.35% |
9.72% |
9.71% |
8.50% |
9.18% |
|
Interest Coverage Ratio
|
10.91 |
216.34 |
285.05 |
134.92 |
138.63 |
|
Revenue Growth Rate (CAGR)
|
-2.06% |
-26.26% |
6.51% |
47.57% |
-1.76% |
Penam Laboratories Limited Income Statement(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
Revenue
|
399.22 |
407.63 |
552.80 |
519.02 |
351.70 |
|
Revenue from operations
|
369.10 |
386.78 |
531.83 |
508.05 |
336.68 |
|
Other income
|
30.12 |
20.85 |
20.97 |
10.97 |
15.02 |
|
Expenses
|
293.58 |
355.02 |
479.69 |
458.93 |
307.47 |
|
Finance cost
|
0.16 |
0.24 |
0.26 |
0.45 |
0.32 |
|
Employee benefit Expense
|
10.66 |
18.17 |
20.77 |
17.97 |
14.88 |
|
Depreciation and Amortisation expense
|
2.02 |
1.92 |
1.95 |
1.90 |
1.86 |
|
Other expenses
|
28.32 |
31.42 |
29.36 |
28.28 |
24.62 |
|
Profit/(loss) before tax
|
105.64 |
52.61 |
73.11 |
60.09 |
44.23 |
|
Tax Expense
|
28.39 |
12.98 |
19.41 |
15.97 |
11.93 |
|
Current tax
|
28.34 |
13.00 |
19.43 |
15.96 |
11.89 |
|
Deferred tax
|
0.05 |
-0.02 |
-0.02 |
0.01 |
0.04 |
|
Profit (Loss) for the period from continuing Operations
|
77.25 |
39.62 |
53.70 |
44.12 |
32.30 |
Penam Laboratories Limited Summary(Rs in Crores)
| Particulars |
2025-26 |
2024-25 |
2023-24 |
2022-23 |
2021-22 |
|
Revenue
|
399.22 |
407.63 |
552.80 |
519.02 |
351.70 |
|
Total Expense
|
0.16 |
355.02 |
479.69 |
458.93 |
307.47 |
|
Operating Expenses
|
135.98 |
51.52 |
52.08 |
48.15 |
41.35 |
|
Employee Expenses
|
2.02 |
18.17 |
20.77 |
17.97 |
14.88 |
|
Operating Income (EBIT)
|
116.31 |
52.85 |
73.37 |
60.54 |
44.56 |
|
Interest Expenses
|
10.66 |
0.24 |
0.26 |
0.45 |
0.32 |
|
Expenses from other activities
|
28.32 |
31.42 |
29.36 |
28.28 |
24.62 |
|
EBITDA
|
144.63 |
54.78 |
75.32 |
62.44 |
46.41 |
|
Net Worth
|
573.53 |
496.22 |
456.58 |
402.97 |
358.76 |
|
Taxes
|
28.39 |
12.98 |
19.41 |
15.97 |
11.93 |
|
Outstanding Shares
|
5,167,157.00 |
5,167,157.00 |
5,167,157.00 |
5,167,157.00 |
5,167,157.00 |
|
Earnings Per Share (EPS)
|
149.51 |
76.68 |
103.93 |
85.38 |
62.51 |
|
Total Assets
|
640.60 |
558.36 |
612.62 |
560.35 |
468.51 |
|
Total Liabilites
|
67.06 |
62.14 |
156.04 |
157.38 |
109.75 |
|
Total equity
|
573.53 |
496.22 |
456.58 |
402.97 |
358.76 |
|
Net cash from/(used in) operating activities
|
54.04 |
-10.53 |
-51.66 |
-23.84 |
34.78 |
|
Net cash from/(used in) investing activities
|
-51.14 |
11.41 |
12.53 |
7.25 |
0.46 |
|
Net cash from/(used) in financing activities
|
0.00 |
|
|
|
|
